MedTrace Logo

Citalopram and Stress Reactivity

NCT04161209 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2019-11-15

No results posted yet for this study

Summary

This study is investigating whether acute administration of citalopram is associated with a decrease in stress reactivity in healthy volunteers, compared to placebo administration. Using a parallel-group double-blind design, participants will be randomised to receive either an acute dose of citalopram or placebo. All participants will have come in for a screening visit. On the day of the research visit (following drug administration) participants will have completed a number of widely used computer-based cognitive tasks measuring emotional processing biases. They will then complete the Oxford Cognition Stress Task, a web-based acute stress induction paradigm, which is designed to induce mild transient increases in stress and arousal. Identifying early changes in stress reactivity following antidepressant treatment will increase the investigator's knowledge of how antidepressants operate, and provide putative targets to identify early response to antidepressants.

Conditions

  • Depression
  • Depressive Disorder
  • Mental Disorder
  • Antidepressive Agents
  • Cognition
  • Stress

Interventions

DRUG

Citalopram

Single dose administration of citalopram (20mg)

OTHER

Placebo

Lactose placebo tablet

Sponsors & Collaborators

  • University of Bath

    collaborator OTHER

  • University of Oxford

    lead OTHER

Principal Investigators

  • Susannah Murphy, DPhil · University of Oxford

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-11
Primary Completion
2020-09-30
Completion
2020-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04161209 on ClinicalTrials.gov